跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 20,702 条关于
“UBE3A-targeting ASO”
全部
20,702
临床试验
5,207
药物
1,205
机构
181
资讯
14,109
去年
Quiver Bioscience Names Co-Founder Graham Dempsey CEO to Advance Nav1.7-Targeting ASO for Chronic Pain
去年
Ionis Pharmaceuticals' ION582 Receives FDA Fast Track Designation for Angelman Syndrome Treatment
3个月前
ASO Targeting ZFP384 Sustains Microglial Repair Activity and Extends Stroke Recovery Window
去年
Ultragenyx Doses First Patient in Phase 3 Aspire Study of GTX-102 for Angelman Syndrome
去年
Ionis' ION582 for Angelman Syndrome Advances to Phase 3 Trial
3个月前
SLC6A20-Targeting ASO Restores NMDA Receptor Function in Autism Models, Offering New Therapeutic Strategy
去年
Sarepta Therapeutics Halts Development of Vesleteplirsen for Duchenne Muscular Dystrophy
上个月
Trace Neuroscience Launches First-in-Human Trials of UNC13A-Targeting ASO for ALS, While EXPERTS-ALS Platform Demonstrates Rapid Drug Screening Capability
3个月前
Developmental and Epileptic Encephalopathies Market Poised for 11.7% CAGR Growth Through 2036, Driven by Next-Generation Gene and Targeted Therapies
去年
Ultragenyx's GTX-102 Shows Promise in Angelman Syndrome Phase 1/2 Trial
第 1 页,共 1411 页
上一页
下一页